At Last, AZ’s Imfinzi/Tremelimumab Cancer Combo Shows Survival Benefit
Could Signal First Tremelimumab Approval
After five years of failure in NSCLC trials, AstraZeneca’s immunotherapy combo shows survival benefits in POSEIDON.
You may also be interested in...
Another day and another fail for AstraZeneca's combination of Imfinzi and tremelimumab, this time for extensive-stage small-cell lung cancer.
Pfizer has unveiled promising results from a study of Xeljanz but needs a bigger trial. Given RECOVERY’s track record, the pharma company may opt to wait for its results.
CureVac is not throwing in the towel just yet, but the odds are stacked against a successful end result.